- Home
- AMSC vs GYRE Comparison
AMSC vs GYRE Comparison
Compare AMSC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSC
- GYRE
- Stock Information
- Founded
- AMSC 1987
- GYRE 2002
- Country
- AMSC United States
- GYRE United States
- Employees
- AMSC N/A
- GYRE N/A
- Industry
- AMSC Metal Fabrications
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AMSC Consumer Discretionary
- GYRE Health Care
- Exchange
- AMSC Nasdaq
- GYRE Nasdaq
- Market Cap
- AMSC 955.6M
- GYRE 897.1M
- IPO Year
- AMSC 1991
- GYRE N/A
- Fundamental
- Price
- AMSC $28.26
- GYRE $9.07
- Analyst Decision
- AMSC Strong Buy
- GYRE
- Analyst Count
- AMSC 3
- GYRE 0
- Target Price
- AMSC $33.67
- GYRE N/A
- AVG Volume (30 Days)
- AMSC 758.6K
- GYRE 337.8K
- Earning Date
- AMSC 05-21-2025
- GYRE 05-09-2025
- Dividend Yield
- AMSC N/A
- GYRE N/A
- EPS Growth
- AMSC N/A
- GYRE N/A
- EPS
- AMSC 0.16
- GYRE 0.02
- Revenue
- AMSC $222,818,000.00
- GYRE $100,643,000.00
- Revenue This Year
- AMSC $15.59
- GYRE $22.01
- Revenue Next Year
- AMSC $15.13
- GYRE $88.14
- P/E Ratio
- AMSC $176.63
- GYRE $112.98
- Revenue Growth
- AMSC 52.99
- GYRE N/A
- 52 Week Low
- AMSC $13.98
- GYRE $6.11
- 52 Week High
- AMSC $38.02
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- AMSC 80.55
- GYRE 45.78
- Support Level
- AMSC $22.85
- GYRE $9.26
- Resistance Level
- AMSC $25.96
- GYRE $11.61
- Average True Range (ATR)
- AMSC 1.44
- GYRE 1.09
- MACD
- AMSC 0.43
- GYRE -0.21
- Stochastic Oscillator
- AMSC 94.31
- GYRE 28.12
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.